Peripheral Foxp3+ regulatory T cells and natural killer group 2, member D expression levels in natural killer cells of patients with colorectal cancer

Shen,Yajuan; Wang,Qian; Qi,Yuanying; Cui,Bin; Zhang,Zhifen; Su,Jingran; Liu,Xiaowen; Lu,Chao; Ye,Hui; Ju,Ying; Lu,Zhiming

doi:10.3892/mmr.2014.2229

Peripheral Foxp3+ regulatory T cells and natural killer group 2, member D expression levels in natural killer cells of patients with colorectal cancer

Authors:
- Yajuan Shen
- Qian Wang
- Yuanying Qi
- Bin Cui
- Zhifen Zhang
- Jingran Su
- Xiaowen Liu
- Chao Lu
- Hui Ye
- Ying Ju
- Zhiming Lu
View Affiliations

Affiliations: Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Clinical Medicine, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: May 13, 2014 https://doi.org/10.3892/mmr.2014.2229
Pages: 977-982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Foxp3+ regulatory T cells (Tregs) and natural killer group 2, member D (NKG2D)-positive natural killer (NK) cells are considered to be important in the immune escape of colorectal cancer (CRC). However, the association between these two variables remains obscure. Therefore, in the present study, the levels of peripheral Tregs and NKG2D expression in NK cells and the associations in CRC patients were investigated. A total of 35 CRC patients and 16 healthy controls were enrolled in this study. Flow cytometry was performed to assay Treg numbers and NKG2D expression levels in NK cells in peripheral blood samples. Serum carcino-embryonic antigen (CEA) protein was assayed by electrochemiluminescence. Peripheral Treg numbers were significantly increased (P<0.05), while NKG2D expression levels in NK cells were significantly reduced (P<0.01) in CRC patients compared with healthy controls. However, no significant differences were identified in Treg numbers between CRC patients with and without lymph node metastases and between CRC patients with different clinical stages of CRC. Similarly, no significant differences were detected in NKG2D expression levels in NK cells between the different patient groups. Statistical analysis revealed that increased Treg numbers were not correlated with reduced NKG2D expression levels in NK cells from CRC patients. In addition, no statistical correlation was observed between Treg numbers and serum CEA protein in CRC patients. In conclusion, the upregulation of Tregs was not significantly correlated with the downregulation of NKG2D expression in NK cells in peripheral blood from CRC patients.

View Figures

View References

1	Sakaguchi S, Miyara M, Costantino CM and Hafler DA: FOXP3⁺ regulatory T cells in the human immune system. Nat Rev Immunol. 10:490–500. 2010.
2	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
3	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ghiringhelli F, Ménard C, Martin F and Zitvogel L: The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 214:229–238. 2006. View Article : Google Scholar : PubMed/NCBI
5	Kohrt HE, Pillai AB, Lowsky R and Strober S: NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol. 40:1862–1869. 2010. View Article : Google Scholar : PubMed/NCBI
6	Clarke SL, Betts GJ, Plant A, et al: CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One. 1:e1292006. View Article : Google Scholar : PubMed/NCBI
7	Trzonkowski P, Szmit E, Myśliwska J, Dobyszuk A and Myśliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 112:258–267. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhou H, Chen L, You Y, Zou L and Zou P: Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity. 43:299–307. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lundqvist A, Yokoyama H, Smith A, Berg M and Childs R: Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 113:6120–6127. 2009. View Article : Google Scholar : PubMed/NCBI
10	Salagianni M, Lekka E, Moustaki A, et al: NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol. 186:3327–3335. 2011. View Article : Google Scholar
11	Ramos RN, Oliveira CE, Gasparoto TH, et al: CD25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses. Carcinogenesis. 33:902–909. 2012. View Article : Google Scholar : PubMed/NCBI
12	Chen YL, Chang MC, Chen CA, Lin HW, Cheng WF and Chien CL: Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One. 7:e471902012. View Article : Google Scholar : PubMed/NCBI
13	Ling KL, Pratap SE, Bates GJ, et al: Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 7:72007.PubMed/NCBI
14	Salama P, Phillips M, Grieu F, et al: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 27:186–192. 2009. View Article : Google Scholar : PubMed/NCBI
15	Brudvik KW, Henjum K, Aandahl EM, Bjørnbeth BA and Taskén K: Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother. 61:1045–1053. 2012. View Article : Google Scholar : PubMed/NCBI
16	Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI
17	Miller AM, Lundberg K, Ozenci V, et al: CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 177:7398–7405. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005. View Article : Google Scholar : PubMed/NCBI
19	de Vries IJ, Castelli C, Huygens C, et al: Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res. 17:841–848. 2011.PubMed/NCBI
20	Sampson JH, Schmittling RJ, Archer GE, et al: A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One. 7:e310462012. View Article : Google Scholar
21	Rech AJ, Mick R, Martin S, et al: CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med. 4:134ra1622012.
22	Lanier LL: NK cell receptors. Annu Rev Immunol. 16:359–393. 1998. View Article : Google Scholar
23	Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 285:727–729. 1999. View Article : Google Scholar : PubMed/NCBI
24	Pende D, Cantoni C, Rivera P, et al: Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 31:1076–1086. 2001. View Article : Google Scholar
25	Ljunggren HG: Cancer immunosurveillance: NKG2D breaks cover. Immunity. 28:492–494. 2008. View Article : Google Scholar : PubMed/NCBI
26	López-Soto A, Huergo-Zapico L, Galván JA, et al: Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol. 190:4408–4419. 2013.PubMed/NCBI
27	Shen Y, Lu C, Tian W, et al: Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol. 40:1285–1290. 2012.PubMed/NCBI
28	Deng L, Zhang H, Luan Y, et al: Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res. 16:4105–4112. 2010. View Article : Google Scholar
29	Okita R, Yamaguchi Y, Ohara M, et al: Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol. 34:563–572. 2009.PubMed/NCBI
30	Xu Q, Lee J, Jankowska-Gan E, et al: Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol. 178:3983–3995. 2007. View Article : Google Scholar : PubMed/NCBI
31	Guerra N, Tan YX, Joncker NT, et al: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 28:571–580. 2008. View Article : Google Scholar : PubMed/NCBI
32	Kanellos I, Zacharakis E, Kanellos D, et al: Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol. 94:3–8. 2006. View Article : Google Scholar : PubMed/NCBI
33	Aggarwal C, Meropol NJ, Punt CJ, et al: Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 24:420–428. 2013. View Article : Google Scholar : PubMed/NCBI